Outcome of therapy-related myeloid neoplasms treated with azacitidine
- Luana Fianchi1,
- Marianna Criscuolo1,
- Monia Lunghi2,
- Gianluca Gaidano2,
- Massimo Breccia3,
- Alessandro Levis4,
- Carlo Finelli5,
- Valeria Santini6,
- Pellegrino Musto7,
- Esther N Oliva8,
- Pietro Leoni9,
- Antonietta Aloe Spiriti10,
- Francesco D’Alò1,
- Stefan Hohaus1,
- Livio Pagano1,
- Giuseppe Leone1 and
- Maria Teresa Voso1Email author
© Fianchi et al.; licensee BioMed Central Ltd. 2012
Received: 24 May 2012
Accepted: 19 July 2012
Published: 1 August 2012
Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation.
We retrospectively evaluated 50 t-MN patients (34 MDS and 16 AML) selected among all patients receiving azacitidine (AZA) at 10 Italian Hematology Centers. Patients had developed a t-MN at a median of 6.5 years (range 1.7- 29) after treatment of the primary tumor (hematological neoplasm, 27 patients; solid tumor, 23 patients).
The overall response rate was 42% (complete remission: 10 patients, partial remission: 2 and hematological improvement: 8 patients) and was obtained after a median of 3 cycles (range 1–6). Median overall survival (OS) was 21 months (range 1–53.6+) from AZA start. OS was significantly better in patients with less than 20% blasts, in normal karyotype t-AML and when AZA was used as front-line treatment. This was confirmed by the multivariate analysis.
This study reports efficacy of AZA in the largest series of therapy-related MN patients treated with 5-AZA. Our data show that blasts and karyotype maintain their important prognostic role in t-MN also in the azacitidine era.
Therapy-related myeloid neoplasms (t-MN) have been recognized as a clinical and biological distinct entity in the 2008 WHO AML classification . By definition, these diseases occur after cytotoxic treatment for a primary cancer or after immunosuppressive treatment. t-MN account for about 10% of all AML, and may arise from few months to several years after the primary tumor, depending on type of cytotoxic treatment, cumulative dose and dose-intensity [2, 3]. At disease onset, t-MN typically present with unfavorable features, such as peripheral blood cytopenias, complex karyotype, and chromosome 11, 5 or 7 abnormalities [4–6]. Increased rates of gene-specific hypermethylation have been reported in t-MN [6–9].
Because performance status is often poor, mostly due to age, primary tumor and exposition to prior therapies, the use of standard chemotherapy protocols is generally impaired in these patients. Treatment varies from supportive care to conventional chemotherapy and allogeneic HSCT, but outcome remains dismal. Even in aggressively treated cases, complete remission rates are usually lower and remission duration is shorter than in de novo MDS/AML, with median survival rates of less than one year in most studies [5, 10–13]. Allogeneic HSCT is the only curative option, but it is not feasible in the majority of patients and is often complicated by high transplantation-related mortality rates . Response rates similar to de novo AML have been recently obtained only for t-AML patients carrying t(15;17) or t(8;21) translocations and included in standard protocols .
During the last few years, hypomethylating agents have been largely used in the treatment of intermediate-2 and high risk MDS . Azacitidine has been shown to be effective also in unfavorable patient sub-groups, inducing response rates up to 60% and improving survival compared to conventional care [14–16].
Here we report that azacitidine treatment might represent a safe and effective option in t-MN patients, given the biological and clinical characteristic of the disease and the potentially fatal consequences of more aggressive therapies.
Patients and methods
In this multicenter study, we retrospectively collected clinical data of patients diagnosed with t-MN and treated with azacitidine (AZA, VidazaTM, Celgene Corp.) at 10 Italian Hematology Centers. Fifty cases of t-MN consecutively treated with AZA were identified and analyzed among all patients with MDS or AML receiving AZA at the participating centers between October 2005 and August 2011. Criteria for AZA treatment were: diagnosis of t-MN according to the WHO classification, defined as leukemias occurring in patients with a history of prior cytotoxic treatment for a primary tumor. Further criteria were adequate renal and hepatic function, and absence of uncontrolled infections. Patients gave written informed consent to treatment and to the collection of clinical data, in accordance with the Declaration of Helsinki and institutional guidelines.
AZA was started at a median of 1.8 months (range 0–29) from t-MN diagnosis, at the conventional dose of 75 mg/m2 daily for 7 days (36 patients, 72%), or at a fixed dose of 100 mg daily for 5, 7 or 10 days (3, 7 and 4 patients, respectively) every 4 weeks. A median of 4 cycles (range 1–23) were administered, with 37.7% of patients receiving 4 or more cycles.
AZA was administered until disease progression, unacceptable toxicity, or patient decision to withdraw consent. Response was assessed according to the modified International Working Group (IWG-2006) criteria [17, 18]. We evaluated overall response (OR), including complete remission (CR), partial remission (PR) and hematological improvement (HI) rates, and overall survival.
Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria (CTC-NCI, version 4.0).
Associations between patient characteristics were analyzed using the Fisher’s exact test. Overall survival was calculated from start of AZA treatment to date of death from any cause or of the last follow-up. Survival curves were estimated using the Kaplan-Meier product limits method. Log-rank test was applied to study survival differences according to patient characteristics. Age (≤ 65 vs >65 y.o.), primary malignancy (hematological vs solid), comorbidity index (HCT-CI) (19), AZA dose (75 mg/m2/7 days vs 100 mg/day 10 days vs 100 mg/day 5 or 7 days), WHO diagnosis (RCMD vs RAEB 1/2 vs AML), karyotype (normal vs abnormal), chromosome 7 abnormalities, transfusion dependence, previous treatment (no vs ESA vs hydroxyurea or chemotherapy) were evaluated in the univariate analysis. Cox proportional hazard model was also used for multivariate analysis of factors with prognostic significance in the univariate analysis (blast count >20%; karyotype, previous cytotoxic treatment for t-MDS/AML). Computations were performed using the Stata 10.0 software (Stata Corp., College Station, TX). All tests were two-sided with α = 0.05.
Clinical characteristics of 50 patients with t-MN treated with azacitidine
n ( range)
Median age (years, median, range)
Type of t-MDS/AML according to the WHO
Primary malignancy :
- Lymphoproliferative disease
- Multiple myeloma
- Chronic myeloproliferative disease
- Breast cancer
Treatment for Primary Malignancy:
- RTx + CTx
Median latency between primary cytotoxic therapy and t-MN diagnosis (years)
Median value at diagnosis (range):
- White blood cell counts (109 /L)
- Platelets (109 /L)
- Bone Marrow blasts (%)
- LDH (UI/L)
Median interval between t-MN diagnosis and AZA treatment (months)
Response to treatment:
- Overall response:
- Stable disease
- Not evaluable
Median cycles number for response
3 (range 1–6)
All patients had previously received chemotherapy (27 patients, 52%), radiotherapy (9 patients, 17%) or a combination of both (14 patients, 27%) for their primary malignancy.
The primary malignancy was a hematological neoplasm in 27 cases (54%), and a solid tumor in 23 cases (46%). t-MN occurred at a median of 6.1 years (range 0.2 - 29.8 years) from treatment of the primary malignancy (Table 1).
Karyotype was evaluable in 47 patients and was normal in 17 (34%), complex (3 or more aberrations) in 20 (43%), and with a single chromosome abnormality in 10 cases (20%). Deletion or monosomy of chromosome 7 was present as single alteration or in the context of a complex karyotype in 14 patients (30%).
Twenty-six patients (52%) were transfusion-dependent before AZA start [median 2 units of red blood cells (range 1–10) /month and median 5 units of platelets /month (range 1–12)]. Four patients had previously received erythropoietin, and 6 patients had previously been treated with hydroxyurea or standard AML induction therapy, while in 40 patients AZA was used as front-line treatment.
Treatment response and overall survival
Treatment response was evaluated in 48 patients (35 MDS and 13 AML) after a median of 3 cycles of AZA (range 1–6). Two patients received only 1 cycle and interrupted treatment on patient’s request (1 patients with stable disease) and due to severe constipation (1 patient). (Table 1). The overall response rate (ORR) was 42%, with complete remission in 10 patients (21%), partial remission in 2 (4.2%) and hematological improvement in 8 patients (16.7%). The disease was stable in 15 patients (31%), while 13 patients (27%) presented disease progression at a median of 4 AZA cycles (range 3–7). Treatment was generally well tolerated. Sixteen patients (32%) experienced grade 3 or 4 myelosuppression including neutropenia (8 patients), thrombocytopenia and neutropenia (7 patients) or anemia (1 patient). Eight patients (16%) developed an infection (pneumonia in 7 patients and sepsis in 1), that was the cause of death in 2 cases (4%). Other grade 3 or 4 non hematological adverse events consisted of erythema at the injection site in 2 cases and constipation in 2 cases.
Median duration of response was 7 months (range 3-47+). Five patients (10%), 4 resistant to AZA, underwent allogeneic stem cell transplantation following azacitidine.
Notably, 5 patients (10%) presented a relapse of the primary malignancy (1 non-Hodgkin lymphoma, 2 breast cancers, 1 bladder cancer and 1 cancer of the uterus) after a median of 4 cycles of AZA (range 2–10), and at a median of 13 years from the diagnosis of the primary malignancy (range 9–26 years). None of the patients died as a consequence of these relapses, but they were resistant to AZA and died due to t-MN progression.
Prognostic factors for overall survival
Number of responders §
≤ 65 years
> 65 years
75 mg/smq/7 days
100 mg/day 10 days
100 mg/day 5 or 7 days
Single or double abnormality
Chromosome 7 abnormalities
Multivariate analysis for overall survival
WHO type (t-AML vs t-MDS)
Karyotype (aberrant versus normal)
Front-line AZA (no vs yes)
Prognosis of patients with therapy-related myeloid neoplasms treated with conventional chemotherapy is poor, with lower remission rates and shorter remission duration than in de novo AML. Furthermore, t-MN display high levels of DNA methylation [6–9] and high frequency of monosomal karyotype, including complete or partial deletions of chromosome 5 or 7 [5, 10, 20].
The biological features and the unsatisfactory results of standard chemotherapy provided the rationale for our retrospective study on the role of azacitidine in t-MN. We observed 42% overall response rate and a median overall survival of 21 months. The outcome of our AZA-treated t-MN patients is similar to results obtained in de novo high-risk MDS treated with AZA at standard doses [14, 21] and also favorably compares to conventional therapy in t-MN [10, 12]. In a recently published study by Kayser et al.. on 200 selected t-AML patients included in 6 prospective German-Austrian multi-center trials, complete response to standard induction therapy was 63% in t-AML, with a median overall survival of about 15 months . There are only few data on AZA efficacy in t-MN. Seventy-four t-MDS were included in a large cohort of 282 high-risk MDS treated with AZA . ORR was 43% for the whole patient cohort, but therapy-related forms had a shorter survival (median 9.2 months versus 15.3 months in de novo MDS, p = 0.002) .
In our study, AZA efficacy was particularly evident in t-MDS, who had a significantly better overall survival than t-AML patients. This was true also considering WHO subgroups, with significantly different overall survival in refractory cytopenia with multilineage dysplasia (RCMD), versus RAEB-1 and −2, versus AML. These data, confirm the role of WHO subgroups in therapy-related as in de novo-MDS [22, 23].
Although karyotype maintains its prognostic value in t-AML, survival of t-AML patients within the same cytogenetic risk group is generally shorter than that of patients with de novo AML . Karyotype prognostic groups differ between MDS and AML. Due to the limited number of patients, especially those with a favorable karyotype, we grouped patients according to the type of t-MN and presence of any chromosomal abnormalities. As a result, our t-AML patients with aberrant karyotype (including chromosome 7 alterations in 30% of cases) had a significantly shorter survival than patients with a normal karyotype. Also, patients treated with AZA front-line had a significantly better outcome than patients who received previous cytotoxic drugs to treat t-MN. In the same line, normal karyotype, bone marrow blast counts below 15% and no previous treatment with low-dose cytosine-arabinoside independently predicted better response to AZA in higher risk MDS . It is also possible that patients treated with cytoreductive chemotherapy had a more aggressive t-MN disease, and thus were less likely to respond to azacitidine when used in second line.
In our series 5 patients had a chronic myeloproliferative disease as previous neoplasm. The inclusion of these disorders into the list of primary malignancies is debated due to possibility that the AML transformation might represent a natural evolution of disease. The exposure to cytotoxic agents however could hasten or induce this transformation as also suggested by an increased risk of AML in patients who were treated with radioactive phosphorus or chlorambucil in the Polycytemia Vera Study Group trial .
Five of fifty patients had a relapse of the previous malignancy during treatment with AZA after a median of 4 cycles, and at a median of 13 years from the diagnosis of the primary malignancy. This observation should be at least a warning to include re-evaluation and monitoring of disease activity of the primary malignancy in future studies on t-MN treatment. There are only very limited data in the literature. More than 20 years ago, Carr et al. reported a higher incidence of testicular tumors after prolonged treatment with AZA in a rat model with an already high spontaneous tumor rate . Itzykson et al did not report any relapse of the primary tumor in 74 t-MDS patients treated with a median of six AZA cycles . On the other hand, AZA efficacy has been reported in solid tumors and lymphoproliferative diseases [27, 28]. Our group has recently reported a patient with Hodgkin lymphoma and a t-MDS, who achieved complete response of MDS and HL following AZA treatment .
In conclusion, our data indicate effectiveness of up-front AZA in t-MN, and are particularly encouraging in the setting of t-MDS. Blasts and karyotype maintain their important prognostic role for t-MN also in the azacitidine era. As there is no accepted standard treatment for patients with t-MN, other treatment approaches in the same time period of our study varied from supportive care only to low-dose cytarabine, gemtuzumab-ozogamicin in combination with G-CSF and cytarabine, standard induction chemotherapy and front-line allogeneic bone marrow transplantation . Only about 25% of t-MN patients registered in 4 of the participating centers were treated with azacitidine. These data will help to design prospective studies for t-MN to address efficacy and risks of AZA treatment, in particular as a less toxic “bridging” therapy to a curative treatment approach as allogeneic transplantation.
This work was supported by grants from Associazione Italiana Ricerca sul Cancro (A.I.R.C.) and FIRB (RBAP11TF7Z).
- Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2008, 114: 937-951.View ArticleGoogle Scholar
- Leone G, Fianchi L, Voso MT: Therapy-related myeloid neoplasms. Curr Opin Oncol. 2011, 23: 672-680. 10.1097/CCO.0b013e32834bcc2a.View ArticlePubMedGoogle Scholar
- Mauritzson N, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Björk J, Strömberg U, Nilsson PG, Mitelman F, Hagmar L, Johansson B: Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001. Leukemia. 2002, 16: 2366-2378. 10.1038/sj.leu.2402713.View ArticlePubMedGoogle Scholar
- Stoddart A, McNerney ME, Bartom E, Bergerson R, Young DJ, Qian Z, Wang J, Fernald AA, Davis EM, Larson RA, White KP, Le Beau MM: Genetic pathways leading to therapy-related myeloid neoplasms. Mediterr J Hematol Infect Dis. 2011, 3: e2011019-PubMed CentralView ArticlePubMedGoogle Scholar
- Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, von Lilienfeld-Toal M, Wilhelm S, Kündgen A, Götze K, Rummel M, Nachbaur D, Schlegelberger B, Göhring G, Späth D, Morlok C, Zucknick M, Ganser A, Döhner H, Schlenk RF: The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011, 117: 2137-2145. 10.1182/blood-2010-08-301713.View ArticlePubMedGoogle Scholar
- Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2003, 17: 1813-1819. 10.1038/sj.leu.2403054.View ArticlePubMedGoogle Scholar
- Greco M, D'Alò F, Scardocci A, Criscuolo M, Fabiani E, Guidi F, Di Ruscio A, Migliara G, Pagano L, Fianchi L, Chiusolo P, Hohaus S, Leone G, Voso MT: Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood Cells Mol Dis. 2010, 45: 181-185. 10.1016/j.bcmd.2010.05.008.View ArticlePubMedGoogle Scholar
- Scardocci A, Guidi F, D'Alo' F, Gumiero D, Fabiani E, Di Ruscio A, Martini M, Larocca LM, Zollino M, Hohaus S, Leone G, Voso MT: Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer. 2006, 95: 1108-1113. 10.1038/sj.bjc.6603392.PubMed CentralView ArticlePubMedGoogle Scholar
- Voso MT, D'Alò F, Greco M, Fabiani E, Criscuolo M, Migliara G, Pagano L, Fianchi L, Guidi F, Hohaus S, Leone G: Epigenetic changes in therapy-related MDS/AML. Chem Biol Interact. 2010, 84: 46-49.View ArticleGoogle Scholar
- Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, Vardiman JW, Rowley JD, Larson RA: Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003, 102: 43-52. 10.1182/blood-2002-11-3343.View ArticlePubMedGoogle Scholar
- Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, Sandmaier BM, Witherspoon RP, Nash RA, Sanders JE, Bedalov A, Hansen JA, Clurman BE, Storb R, Appelbaum FR, Deeg HJ: Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: Similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007, 110: 1379-1387. 10.1182/blood-2007-02-076307.PubMed CentralView ArticlePubMedGoogle Scholar
- Larson RA, Le Beau MM: Prognosis and therapy when acute promyelocytic leukemia and other "good risk" acute myeloid leukemias occur as a therapy-related myeloid neoplasm. Mediterr J Hematol Infect Dis. 2011, 3: e2011032-PubMed CentralView ArticlePubMedGoogle Scholar
- Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001, 98: 1312-1320. 10.1182/blood.V98.5.1312.View ArticlePubMedGoogle Scholar
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR: Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009, 10: 223-232. 10.1016/S1470-2045(09)70003-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P: Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011, 117: 403-411. 10.1182/blood-2010-06-289280.View ArticlePubMedGoogle Scholar
- Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, Pomplun S, Thomas NS, Mufti GJ: CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with azacitidine. Leukemia. 2007, 21: 1937-1944. 10.1038/sj.leu.2404796.View ArticlePubMedGoogle Scholar
- Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Löwenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD: Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003, 21: 4642-4649. 10.1200/JCO.2003.04.036.View ArticlePubMedGoogle Scholar
- Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006, 108: 419-425. 10.1182/blood-2005-10-4149.View ArticlePubMedGoogle Scholar
- Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B: Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005, 106: 2912-2919. 10.1182/blood-2005-05-2004.PubMed CentralView ArticlePubMedGoogle Scholar
- D'Alò F, Fianchi L, Fabiani E, Criscuolo M, Greco M, Guidi F, Pagano L, Leone G, Voso MT: Similarities and differences between therapy-related and elderly acute myeloid leukemia. Mediterr J Hematol Infect Dis. 2011, 3: e2011052-PubMed CentralView ArticlePubMedGoogle Scholar
- Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR: Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010, 28: 562-569. 10.1200/JCO.2009.23.8329.View ArticlePubMedGoogle Scholar
- Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M: Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005, 23: 7594-7603. 10.1200/JCO.2005.01.7038.View ArticlePubMedGoogle Scholar
- Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellström-Lindberg E: The WHO Classification of MDS does make a difference. Blood. 2004, 103: 3265-3270. 10.1182/blood-2003-06-2124.View ArticlePubMedGoogle Scholar
- Kern W, Haferlach T, Schnittger S, Hiddemann W, Schoch C: Prognosis in therapy related acute myeloid leukemia and impact of karyotype. J Clin Oncol. 2004, 22: 2510-2511. 10.1200/JCO.2004.99.301.View ArticlePubMedGoogle Scholar
- Murphy S: Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost. 1997, 78: 622-626.PubMedGoogle Scholar
- Carr BI, Rahbar S, Asmeron Y, Riggs A, Winberg CD: Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. Br J Cancer. 1988, 857: 395-402.View ArticleGoogle Scholar
- Stathis A, Hotte SJ, Chen EX, Hirte HW, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL: Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res. 2011, 17: 1582-1590. 10.1158/1078-0432.CCR-10-1893.View ArticlePubMedGoogle Scholar
- Boumber Y, Issa JP: Epigenetics in cancer: what's the future?. Oncology. 2011, 25: 220-226. 228PubMedGoogle Scholar
- D'Alò F, Leone G, Hohaus S, Teofili L, Bozzoli V, Tisi MC, Rufini V, Calcagni ML, Voso MT: Response to azacitidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome. Br J Haematol. 2011, 154: 141-143. 10.1111/j.1365-2141.2010.08438.x.View ArticlePubMedGoogle Scholar
- Fianchi L, Pagano L, Leoni F, Storti S, Voso MT, Valentini CG, Rutella S, Scardocci A, Caira M, Gianfaldoni G, Leone G: Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. Ann Oncol. 2008, 19: 128-134.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.